Premier Alternatives

InGel Therapeutics

Allston, MA · Founded 2022 · Privately Held (backing)

Developer of engineered cell therapy designed to target neuroprotective pathways to treat retinal degeneration. InGel Therapeutics is based in Allston, MA and was founded in 2022. It was valued at $17 million at its seed round in Jul 2024, the last priced event on record. It has raised $10.8 million across 1 recorded round; the latest was a $350,000 seed round in Jul 2022.

PMV mark · valuation
$17.0M
Oct 2026
Priced at
its seed round
Jul 2024
Total raised
$10.8M
Last round
Seed Round
Jul 2022

InGel Therapeutics key facts

as of Oct 2026
  • Developer of engineered cell therapy designed to target neuroprotective pathways to treat retinal degeneration.
  • InGel Therapeutics is valued at approximately $17.0M as of Oct 2026, set at its seed round, Jul 2024; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $10.8M across 1 recorded rounds; the latest was Seed Round ($350K) in Jul 2022.
  • Notable investors include Alumni Ventures, Service Provider Capital, Calm Ventures, Endless Frontier Labs, Harvard Innovation Launch Lab — 16 tracked in total.
  • InGel Therapeutics has filed 1 Form D with the SEC, most recently Aug 2022 ($350K sold to 4 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$17.0M

Valued at $17.0M at its seed round, Jul 2024. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of InGel Therapeutics with a free account
  • ·The complete investor list: 16 names
  • ·Watch InGel Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

InGel Therapeutics funding rounds

1 rounds
Jul 2022Seed Round$350KSEC filing▮
Full funding history →

InGel Therapeutics valuation

InGel Therapeutics was valued at $17 million at its seed round in Jul 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has InGel Therapeutics raised?

InGel Therapeutics has raised $10.8 million in total; 1 of its rounds is on record. The largest on record was a $350,000 seed round in Jul 2022.

InGel Therapeutics has filed 1 Form D with the SEC, most recently in Aug 2022 ($350,000 sold to 4 investors).

InGel Therapeutics investors

16 investors are on record for InGel Therapeutics, including Alumni Ventures, Service Provider Capital, Calm Ventures and Endless Frontier Labs. By type, the record holds 7 venture capital firms. The seed round in Jul 2022 drew 4 investors.

About InGel Therapeutics

Developer of engineered cell therapy designed to target neuroprotective pathways to treat retinal degeneration. The company utilizes stem cells and their secretome for neuroprotection for blinding diseases like retinitis pigmentosa and macular degeneration through biodegradable polymers to isolate proteins of neuroprotective significance first in vitro and later in vivo, enabling healthcare professionals to treat the retinal degeneration of patients.

Sector
Healthcare
HQ
Allston, MA, United States
Founded
2022
Employees
8
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.